1. Introduction {#s0005}
===============

Ubiquitination of proteins is a reversible post-translational modification that is critical for almost any cellular process. The control of these crucial pathways lies in the precise regulation of ubiquitinating and deubiquitinating enzymes (DUBs). DUBs are carefully regulated intra-cellular peptidases that cleave ubiquitin from target substrates. There are approximately 90 DUBs in the human genome, in 5 different families ([@b0020], [@b0115]). The most abundant are the ubiquitin specific proteases (USPs) with 60 members that share a conserved USP catalytic domain, in which the ubiquitin core is held by the "fingers" while the catalytic centre lies between the "palm" and "thumb" subdomains. Despite this common catalytic core, the USP family members have many different modes of regulation ([@b0185]).

Such regulation can take place in different ways and at different sites. USPs are regulated by changes in the catalytic domain, where the catalytic triad may be misarranged ([@b0075]), via additional domains within the protein itself ([@b0025], [@b0045]), via post translational modifications ([@b0165]), or by sub-cellular localization ([@b0180]). An interesting form of regulation is seen in a small sub-family of USPs, that includes USP1, USP12 and USP46. These three proteins are activated by complex formation with a WD40 repeat protein called UAF1 (USP1 associated factor, also known as WDR48) that leads to increased catalytic turnover for these enzymes ([@b0035]).

USP12 and USP46 are small proteins (370 and 366 residues respectively) with a highly conserved catalytic domain and high sequence similarity (88% identity). The related paralog USP1 (31% identity) is much larger (785 residues), due to additional inserts within its catalytic domain. The USP12/UAF1 and USP46/UAF1 complex can be further activated by binding to a second WD repeat protein, WDR20. This hyper-activation is not observed for the USP1/UAF1 complex ([@b0110]). The lack of hyper-activation in USP1 could be due to the presence of the long inserts which might prevent it from interacting with WDR20. All three enzymes have low intrinsic activity in isolation and binding to UAF1 leads to activation which was shown to be due to an increase in k~cat~ with no drastic change in the K~M~ ([@b0035], [@b0050], [@b0210]). The exclusive k~cat~ activation is unusual for DUBs as most intermolecular activators (except GMPS) affect substrate binding ([@b0050]).

The UAF1 regulation of this subfamily of DUBs has attracted considerable attention due to the biological importance of the enzymes involved. USP1 is important in DNA repair, where it acts on mono-ubiquitinated FANCD2 and PCNA in DNA cross-link repair and DNA-damage avoidance pathways ([@b0080], [@b0170]). It is also found to deubiquitinate the ID family of transcriptional regulators ([@b0220]). Due to these important functions, USP1 is considered a major possible drug target ([@b0145]). USP46 plays important roles in neurobiology, as a small deletion mutation in USP46 leads to neurological effects in mice, including anxiety and changes in learning and memory ([@b0085], [@b0235]). The molecular basis for these effects is not yet clear. For USP12 several possible roles have been described. It is involved in stabilizing the Akt phosphatases resulting in decreased levels of pAkt ([@b0065]). It has also been reported that USP12 and USP46 deubiquitinate histone H2A and H2B thereby playing a role in Xenopus development ([@b0095]). Recently USP12 was shown to stabilize the T-cell receptor complex at the cell surface by deubiquitinating TCR adaptor proteins LAT and Trat1 ([@b0090]).

Several studies have tried to uncover the detailed mechanism of USP1/12/46 activation by UAF1 and also the interfaces involved in the formation of this complex. It was suggested that UAF1 binding modulates the active site conformation of USP1 resulting in a productive catalytic triad and also that phosphorylation of Ser313 is necessary for its interaction ([@b0210], [@b0215]). Other studies have shown that the regions in and around the fingers domain of USP1 might be necessary for UAF1 binding ([@b0175]). Recently the crystal structure of the USP46-Ub and its complex with UAF1 were determined. In these structures two possible interfaces for UAF1 binding and activation were identified. The authors used mutational analysis to show that Interface 1 is critical for UAF1 binding and activation ([@b0230]).

Here we present the structure of USP12-Ub/UAF1~580~ complex which was solved at a resolution of 2.8 Å and compare it to the UAF1 structure alone. Intriguingly, we find that these structures resemble the USP46/UAF1 complex structure ([@b0230]), including the presence of the second binding site. We then show that in solution USP12 can bind to a second molecule UAF1, but with lower affinity. We confirm for USP12 that Interface 1 at the fingers site is the high affinity interface while the second low affinity interface could be at the backside of the ubiquitin binding cleft. Moreover, mutagenesis studies suggest that the first binding event at the fingers is responsible for activation while the second binding does not influence activity.

2. Materials and methods {#s0010}
========================

2.1. Plasmids and cloning {#s0015}
-------------------------

Human USP12, USP46, USP1 and UAF1 constructs were obtained from Martin Cohn. The USPs were cloned into pFastbac-HTb vector and UAF1 was cloned into pFastbac1 (N-terminal Strep tag) for insect cell expression. The sequence verified insert containing pFastbac vectors were transformed into DH10Bac cells for bacmid preparation. The recombinant bacmid was used for transfection of *Spodoptera frugiperda* (*sf*9) insect cells to produce the recombinant baculovirus. USP12~WT~ (24--370) and USP46 (8--366) were also cloned into the pGEX and pET bacterial expression vectors of the NKI LIC suite, respectively ([@b0150]). All USP12 mutants were made using the QuikChange site directed mutagenesis method on pGEX USP12 bacterial construct.

2.2. Protein expression and purification {#s0020}
----------------------------------------

N-terminal His-tagged USP1 (21--785) and USP12~FL~ were expressed using Baculovirus expression in *sf*9 insect cells. After 72 h of infection the cells were harvested in 20 mM Tris (pH 8.0) + 200 mM NaCl + 2 mM TCEP + protease inhibitor (lysis buffer) and lysed by sonication. The lysed cells were spun down (21,000 rpm for 1 h) and the lysate was loaded on a His-affinity column (GE, USA). The column was washed with lysis buffer supplemented with 50 mM Imidazole (pH 8.0) followed by elution with lysis buffer supplemented with 500 mM imidazole. The His-USP1 elution fractions were concentrated and loaded on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer (20 mM HEPES (pH 7.5) + 150 mM NaCl + 2 mM DTT) following which the protein fractions were concentrated up to 4.5 mg/ml and stored in −80 °C. The USP12~FL~ and USP46~FL~ fractions were incubated with TEV protease and dialyzed overnight in lysis buffer without imidazole. The dialysed protein sample was then loaded on a His-affinity column where the protein was obtained in the wash fractions. The protein containing fractions were then concentrated and loaded on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer following which protein fractions were concentrated up to 6 mg/ml and stored in −80 °C.

N-terminal GST-tagged USP12~WT~ and mutants were expressed in *E. coli*. The cells were induced with 0.2 mM IPTG at 18 °C for 10--12 h followed by which they were harvested in lysis buffer and lysed by sonication. The lysate was loaded on a GST-affinity column and washed with lysis buffer followed by elution with lysis buffer supplemented with 20 mM Glutathione. The protein containing fractions were then concentrated and loaded on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer following which protein fractions were concentrated up to 15 mg/ml and stored in −80 °C.

N-terminal His-tagged USP46 (8--366) was expressed in *E. coli*. The cells were induced with 0.5 mM IPTG at 20 °C for ∼16 h followed by which they were harvested in 20 mM Tris (pH 7.5), 150 mM NaCl, 10 mM Imidazole (pH 8.0) and 5 mM beta-mercaptoethanol (lysis buffer) and lysed by sonication. The lysate was loaded on a Ni-affinity column and washed with lysis buffer supplemented with 50 mM imidazole followed by elution with lysis buffer supplemented with 500 mM imidazole. USP46 was incubated with TEV protease and dialysed overnight in lysis buffer without imidazole. The dialysed protein sample was then loaded on a His-affinity column where the protein was obtained in the wash fractions. USP46 was loaded on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated with 20 mM Tris (pH 7.5), 150 mM NaCl and 2 mM DTT.

UAF1~FL~ and UAF1~580~ were also purified from *sf*9 insect cells and were lysed in similar conditions as the USP purifications. The UAF1 lysates were loaded on a Strep-affinity column (IBA life sciences) and washed with 50 mM Tris (pH 8.0) + 150 mM NaCl + 2 mM TCEP (wash buffer). The strep-UAF1 protein was then eluted using wash buffer supplemented with 2.5 mM Desthiobiotin. The protein containing fractions were concentrated and loaded on a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer. The fractions corresponding to the peak were collected. UAF1 samples were treated with 10 mM iodoacetamide to prevent background DUB activity due to minute amounts of co-purified insect cell DUBs. Following iodoacetamide treatment the protein fractions were re-purified using size exclusion chromatography (Superdex 200, GE, USA). The protein fractions were then concentrated up to 10 mg/ml and stored in −80 °C.

The USP/UAF1 complexes were co-expressed in baculovirus infected *sf*9 insect cells. USP/UAF1 complexes were purified by first carrying out a His-affinity purification followed by Strep-tag (IBA life Sciences) affinity purification as described above. The protein fractions were then concentrated and loaded on a size exclusion chromatography (Superdex S200, GE, USA) equilibrated in GF buffer. The protein containing fractions were concentrated up to 5 mg/ml and stored at -80 °C.

Covalent complexes of USP46 and USP12~FL~/UAF1~580~ with Ub-VME and Ub-PRG respectively were generated under reducing conditions at 4 °C for 12--16 h. The USP46 reaction was very slow and only 50% of the enzyme reacted to Ub-VME whereas approximately 80% of the USP12~FL~/UAF1~580~ complex reacted to the Ub-PRG probe. The reacted USPs were then purified from the excess probe by using a size exclusion chromatography column (Superdex 200, GE, USA) equilibrated in GF buffer. The purified USP-Ub complex was then concentrated and stored at -80 °C.

2.3. Crystallization and structure determination {#s0025}
------------------------------------------------

USP12 and UAF1 crystals were obtained by sitting drop vapour diffusion experiment at 20 °C using equal ratio of protein and mother liquor solution. UAF1~580~ was setup for crystallization at 8 mg/ml and crystals were obtained in 20% PEG3350, 200 mM Tri-Sodium Citrate, Bis-Tris Propane pH 6.5. USP12~FL~-Ub-PRG/UAF1~580~ was setup at 5 mg/ml and crystals were obtained in 3.2% PEG4000, 0.1 mM MMT pH 6.5 and 0.1 mM TCEP. The crystals were cryo-protected by brief washing in mother liquor solution with 30% glycerol prior to flash freezing in liquid nitrogen. Diffraction data were collected at the Swiss Light Source beamline PXIII at 100 K.

USP46-Ub-VME at 8 mg/ml was set up for crystallization by sitting drop vapour diffusion experiment at 20 °C. Crystals were obtained in 0.96 M Sodium Citrate pH 7.5 and 0.1 mM ZnCl~2~ with protein: precipitant ratio 1.5: 1. The crystals were cryo-protected by brief washing in mother liquor solution with 20% glycerol prior to flash freezing in liquid nitrogen. Diffraction data were collected at the European Synchrotron Radiation Facility (ESRF) beamline ID14-1 at 100 K.

Crystallographic data were processed with XDS ([@b0105]) or iMOSFLM ([@b0010]) and scaled using XSCALE ([@b0105]) or Aimless from the CCP4 suite ([@b0225]). The USP46-Ub-VME structure was solved by molecular replacement using the USP2-Ub model (PDB [2IBI](pdb:2IBI){#ir005}) in Phaser ([@b0155]) followed by automated model building using ARP/WARP ([@b0135]). The UAF1 (9--580) structure was solved by molecular replacement (PDB-1VYH) in Phaser ([@b0155]) followed by automated model building using ARP/Warp ([@b0135]). The USP12~FL~-Ub/UAF1~580~ structure was solved by molecular replacement using the USP46, UAF1~580~ and ubiquitin structures as search models in Phaser. All structures were refined by Phenix ([@b0005]), autoBUSTER ([@b0190]), Refmac ([@b0160]), PDB_REDO ([@b0100]) and models were built using COOT ([@b0040]). Interface analysis was performed with PISA ([@b0130]). All structure figures were generated using PyMOL (Schrödinger, LLC).

2.4. Size exclusion chromatography Multi Angle Laser Light Scattering (SEC-MALLS) {#s0030}
---------------------------------------------------------------------------------

The SEC-MALLS experiments were performed using the miniDawn Tristar light scattering detector (Wyatt technologies, USA) in line with size exclusion chromatography. After equilibration of the Superdex 200 10/300 GL and the Superose 6 increase 10/300 GL (GE, USA) in buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 2 mM DTT, the USP12~FL~-Ub/UAF1~580~ (8 μM) and the USP1/UAF1~FL~ complex (6 μM) were loaded on the Superdex 200 10/300 GL while the USP12~FL~-Ub/UAF1~FL~ sample (42 μM) was loaded on the Superose 6 increase 10/300 GL (GE, USA). Molecular weight estimation was done by using the refractive index signal as measure of the concentration with the Astra software (Wyatt Technologies, USA).

2.5. Size exclusion chromatography -- small angle X-ray scattering (SEC-SAXS) {#s0035}
-----------------------------------------------------------------------------

USP12~FL~-Ub/UAF1~FL~ purified from insect cells was concentrated up to 38 μM. The buffer used for the size exclusion chromatography was also used for SEC-SAXS experiment on the BM29 SAXS beamline at the ESRF. Following equilibration, 30 μl of the purified USP12~FL~-Ub/UAF1~FL~ was loaded on the Superdex 200 5/150 GL (GE, USA) and 1500 successive 1 s frames were collected through the protein elution peak. The data were normalized to the intensity of the transmitted beam and radially averaged; the scattering of the solvent-blank (derived from the buffer run) was subtracted. Data were analysed using the ATSAS software package ([@b0205]). A moving set of 10 or 20 frames was analysed across the high-intensity peak to estimate molecular weight from various methods (DATPOROD ([@b0120]), excluded volume from DAMMIF model ([@b0060]) and SAXS MoW2 ([@b0055])) and fit the data to the crystallographic structures in CRYSOL ([@b0200]). Frames prior to 670 and frames latter than 910 were considered too noisy or weak for analysis. OLIGOMER ([@b0125]) was used to perform a fit to the experimental curve from different possible models of the complex and determine volume fractions of each component. Several OLIGOMER runs were performed using the 2:1 complex, both 1:1 complexes and UAF1 alone as models in different combinations.

2.6. Ub-rhodamine enzymatic assays {#s0040}
----------------------------------

Enzymatic activity was followed as release of fluorescent rhodamine from the quenched Ub-Rho substrate, providing a direct readout for DUB activity. The fluorescent intensity was measured using Pherastar plate reader (BMG LABTECH GmbH, Germany). Activity of USP12~WT~ at varying concentrations of UAF1~FL~ (20--1250 nM) was tested at 100 nM of USP12~WT~ and at a single substrate concentration of 1 μM. Activity was quantified by calculating the initial rates and plotted as a function of UAF1~FL~ concentration. 100 nM of enzyme was used against different concentrations of the minimal substrate (32--0.25 μM) for the Michaelis Menten analysis. The initial rates were then plotted against substrate concentration and fitted with a Michaelis Menten model using non-linear regression in GraphPad Prism 6 software (GraphPad Software Inc, USA).

2.7. Binding assays {#s0045}
-------------------

Surface Plasmon Resonance experiments were carried out to test binding of His-USP1 and Gst-USP12~WT~ to UAF1~FL~ in the Biacore T200 system (GE, USA). The SPR buffer for Gst-USP12~WT~ and mutants consisted of 20 mM HEPES 7.5, 150 mM NaCl, 20% glycerol, 0.05% Tween-20, 2 mM TCEP (Tris (2-carboxyethyl) phosphine hydrochloride) and 1 mg/ml dextran. The SPR buffer for His-USP1 had 300 mM NaCl to neutralize any unspecific interaction with Ni on the chip surface and the rest of the components were identical. The Gst-USP12 was immobilized via goat anti-GST antibody that was pre immobilized to the CM5 chip using amine coupling. The His-USP1 was directly immobilized to the surface of NTA chip via His-tag. The binding experiments were carried out in the single cycle kinetics mode with 5 sequential injection of UAF1~FL~ in each cycle. An initial experiment with 5 injections from 1 nM to 10 μM and a more detailed assay with 15 injections from 0.56 nM to 2.56 μM were carried out. Data from a reference flow cell, run in parallel with an empty chip (in case of NTA immobilization) or with GST (in case of anti-GST immobilization) were subtracted from the signal using the Biacore T200 Evaluation Software. Final analysis and the figures were done using GraphPad Prism 6 (GraphPad Software Inc, USA).

3. Results {#s0050}
==========

3.1. Crystal structures of USP46, UAF1~580~ and USP12~FL~-Ub/UAF1~580~ complex {#s0055}
------------------------------------------------------------------------------

To study how the regulator UAF1 modulates the activity of USPs, we purified the human USP46, human USP12 and several constructs of the human UAF1. We refer to UAF1 (9--580) as UAF1~580~ and to UAF1 (9--677) as UAF1~FL~ ([Fig. 1](#f0005){ref-type="fig"}a). By reaction of USP46 and USP12 with suicide inhibitors of ubiquitin, Ub-VME and Ub-PRG respectively, we could create covalently linked USP-Ub complexes, which were used for crystallization attempts.

We generated well diffracting crystals for USP46-Ub (1.85 Å), USP12~FL~-Ub/UAF1~580~ (2.8 Å) and UAF1~580~ (2.3 Å). All three crystal structures were solved by molecular replacement where the covalent USP2-Ub complex model (2IBI) was used for the USP46-Ub structure and the protein PAF-AH (1VYH) was used as a model for UAF1~580~. The resulting structures of USP46-Ub and UAF1~580~ were used as models for the USP12~FL~-Ub/UAF1~580~ complex. All three structures were refined to acceptable R-factors and good geometry ([Table.1](#t0005){ref-type="table"}).

The crystal structure of USP46-Ub reveals the canonical USP domain with a catalytic centre in the catalytically proficient state ([Fig. 1](#f0005){ref-type="fig"}b). The crystallization contained only 50% of the Ub-bound form, but the crystal was fully modified, indicating a preferential crystallization of the ubiquitin-bound form. This structure is in good agreement with the recently published structure of USP46 ((5CVM), RMSd on 308 C~α~: 0.3 Å). The structure of UAF1~580~ forms a 7 bladed β-propeller with an ancillary domain ([Fig. 1](#f0005){ref-type="fig"}c), although WD40 domain predictions obtained from the protein sequence predicted 8 blades. The first N-terminal residues (13--24) are present in the ancillary domain and the following residues from 25 to 360 form the 7 bladed β-propeller. The predicted eighth blade (361--400) forms the expected 4-stranded sheet but is located in the ancillary domain where it sits on top of a β sheet in which the N-terminal residues form an integral part. The UAF1~580~ structure is very similar to the recently published structure of UAF1 ((5CVL), RMSd on 517 C~α~: 1.2 Å).

In the crystal lattice of the USP12~FL~-Ub/UAF1~580~ complex, the asymmetric unit contains one molecule of USP12 and one molecule of UAF1. However, USP12 makes two possible interfaces with UAF1 in these crystals, one on the fingers sub-domain (Interface 1) ([Fig. 1](#f0005){ref-type="fig"}d, e) and the other on the backside of the ubiquitin binding cleft (Interface 2) ([Fig. 1](#f0005){ref-type="fig"}f, g). The interactions in Interface 1 are dominated by hydrophilic and charged interactions, with 794 Å^2^ and 698 Å^2^ buried surface area on USP12 and UAF1~580~ respectively ([Fig. 1](#f0005){ref-type="fig"}e). The Interface 2 is mostly hydrophobic and buries a surface area of 1030 Å^2^ and 1111 Å^2^ on USP12 and UAF1~580~ respectively ([Fig. 1](#f0005){ref-type="fig"}g). Intriguingly the same crystal packing was seen for the USP46/UAF1 complex (PDB code: [5CVN](pdb:5CVN){#ir010}) that was published during the refinement of our structures ([@b0230]). In that publication the authors confirmed by mutational analysis that Interface 1 is the relevant interface for activation. USP46/UAF1 was crystallized in the same space group, with similar cell dimensions, which is not surprising since USP12 and USP46 have 88% sequence similarity, although neither interface is fully conserved. A second crystal form for USP46/UAF1~FL~ was determined in a different crystal lattice (C2), with different packing, but even in this crystal lattice, the USP still has maintained both interfaces (PDB code: [5CVO](pdb:5CVO){#ir015}). The striking similarity and conservation of these two USP/UAF1 interfaces among three different crystal structures suggested that this was not due to a crystal packing artefact and further analysis of the second interface would be worthwhile ([Supp. Fig. 1a](#s0100){ref-type="sec"}).

A superposition of our USP46 structure on USP12 in complex with UAF1~580~ revealed no significant conformational change in the USP moiety (RMSd on 309 C~α~: 0.9 Å). When the UAF1 moieties are compared by superposition of the UAF1~580~ onto the USP12~FL~-Ub/UAF1~580~ complex, no conformational change is observed in UAF1~580~ close to Interface 1 ([Supp. Fig. 1b](#s0100){ref-type="sec"}), whereas a large shift is observed in the extended loop of blade 3, the region where UAF1~580~ forms Interface 2 ([Supp. Fig. 1c](#s0100){ref-type="sec"}). This conformational change due to interaction of UAF1~580~ at Interface 2 is also observed in the USP46/UAF1 structure upon UAF1 binding ([@b0230]). Since the conformational change as well as the presence of two UAF1 interfaces seems to be conserved between USP46 and USP12, we wondered what stoichiometry the USP12/UAF1 complex has in solution.

3.2. The USP12/UAF1 complex has 1:2 stoichiometry {#s0060}
-------------------------------------------------

To study relative amounts of USP12 and UAF1 in solution we carried out size exclusion chromatography coupled with multi-angle laser scattering (SEC-MALLS) of the purified USP12~FL~-Ub/UAF1~580~ complex which was used for obtaining the crystal structure. The molecular weight obtained from the MALLS experiment was approximately 166 KDa which is much closer to the calculated mass for 1:2 complex (180 KDa) than for a 1:1 complex (115 KDa). The calculated molecular weight was not constant within the peak, which suggests a dynamic equilibrium between the 1:2 and 1:1 complexes ([Fig. 2](#f0010){ref-type="fig"}a).

Next, we carried out small angle X-ray scattering (SAXS) experiments coupled to size exclusion chromatography. At the high concentration necessary for SAXS experiments higher order species are observed ([Fig. 2](#f0010){ref-type="fig"}b). The purified complex of USP12~FL~ with covalently bound Ub-PRG and UAF1~FL~ was used for these experiments. Frames corresponding to the different parts of the peak were averaged and analysed separately ([Supp. Fig. 1](#s0100){ref-type="sec"}e). Molecular weight estimation of the data (898--909) from the latter half of the peak was consistent, when carried out using different methods (Porod volume ([@b0120]), excluded volume from DAMMIF model ([@b0060]), and SAXS MoW2 ([@b0055])), where we observed that USP12~FL~-Ub/UAF1~FL~ has a molecular weight of 190 KDa corresponding to a 1:2 stoichiometry of the complex. Additionally, Porod analysis of the frames in the early half of the peak corresponded to a molecular weight of 390 KDa indicating formation of high molecular weight species which fits well with the MALLS data ([Fig. 2](#f0010){ref-type="fig"}b).

Moreover, we compared the experimental SAXS profile of frames (898--909) with calculated scattering curves based on the crystal structure either with one UAF1~FL~ bound (in either of the two sites), or with two UAF1~FL~ molecules bound. We obtained a much worse fit with the 1:1 profiles ([Fig. 2](#f0010){ref-type="fig"}c, e) compared to the possible 1:2 profile ([Fig. 2](#f0010){ref-type="fig"}d). To further analyse these data, we tested whether the OLIGOMER algorithm would change the fit. Other possible options did not improve the fit, but when testing for the 1:2 profile, we found an improved fit ([Fig. 2](#f0010){ref-type="fig"}f) with volume fractions of 81% for the 1:2 complex and a smaller fraction for UAF1~FL~ (19%). In principle such a fraction was expected to be a mixture of the 1:1 complex and UAF1~FL~. It is possible that the computational analysis selects against this complex mixture when fractions are small.

3.3. UAF1 binds USP12 in two distinct steps with different affinities {#s0065}
---------------------------------------------------------------------

We investigated if the two binding events indicative of the 1:2 stoichiometry could be observed in an *in vitro* binding experiment. Therefore, we analysed the binding of UAF1~FL~ to GST-USP12~WT~ by Surface Plasmon Resonance (SPR) and indeed observed two distinct binding events ([Fig. 3](#f0015){ref-type="fig"}a). We found a high-affinity binding (K~d~ = 4 nM) with an extremely low off-rate, which saturated at 100 nM. Moreover, when we added higher concentrations of UAF1~FL~, a second binding event could be observed (K~d~ = 325 nM) ([Fig. 3](#f0015){ref-type="fig"}b) with faster binding and dissociation. In conclusion, we observed two binding events for UAF1~FL~ binding to USP12~WT~ with different binding characteristics.

We tested which of these events contributed to activation. We performed an enzymatic assay against the minimal substrate ubiquitin rhodamine (Ub-Rho), as a function of activator concentration. We could see a clear activation that correlates with the high-affinity binding site. In contrast, the second binding event does not affect the activation status, as no further activation is observed when the UAF1~FL~ binds the second site ([Fig. 3](#f0015){ref-type="fig"}c, d). We then performed a kinetic analysis of USP12 activity, either at equal concentration to UAF1 (1:1) or when an excess of UAF1 is present ([Fig. 3](#f0015){ref-type="fig"}e). The Michaelis Menten parameters K~cat~ and K~M~ did not change with higher UAF1 concentration, confirming that only Interface 1 is important for UAF1 mediated USP12 activation ([Table 2](#t0010){ref-type="table"}).

3.4. The Fingers sub-domain in USP12 is crucial for binding and activation by UAF1 {#s0070}
----------------------------------------------------------------------------------

We validated the role of Interface 1 by making a series of mutations. In line with their role in the USP46/UAF1 interface ([@b0230]), a triple mutant (UAF1~3X~ = K214E + W256A + R272D) on UAF1 and a reciprocal mutant (E190K) on USP12 interfered with high affinity binding ([Fig. 4](#f0020){ref-type="fig"}a, b). The high affinity binding could be partially rescued by combining the USP12~E190K~ with the UAF1~3X~ mutant, in a similar fashion to what was observed for USP46 and UAF1 binding ([Fig. 4](#f0020){ref-type="fig"}c) ([@b0230]). Additionally, the binding of the USP12~E190K~ to the low affinity site remained unchanged. On comparing the binding characteristics of these mutants with USP12~WT~, we noted that the UAF1~3X~ mutant only binds at very high concentrations and does not release easily, while the USP12~E190K~ mutant binds with a fast release ([Fig. 4](#f0020){ref-type="fig"}a). We also made a series of mutations at Interface 2 on USP12~WT~, by either reversing charges (R217E or R285D) or changing the hydrophobic interface (F287A) but none of them could disrupt binding of UAF1 to this site ([Fig. 4](#f0020){ref-type="fig"}g, h).

We then carried out an *in vitro* Ub-Rho assay to analyse the effects of these mutations on USP12 activation and compare it with previously published findings for USP46 ([@b0230]). Wild type UAF1 was unable to activate USP12~E190K~ to similar levels as compared to USP12~WT~ ([Fig. 4](#f0020){ref-type="fig"}d, e) and similarly, the UAF1~3X~ mutant did no longer activate. However, as shown previously for USP46/UAF1 ([@b0230]), the combination of these complementary mutants rescues the activation ([Fig. 4](#f0020){ref-type="fig"}f), highlighting the importance of the fingers sub domain in USP12 and USP46 ([@b0230]) activation by UAF1.

3.5. The two-step binding is conserved in USP1 {#s0075}
----------------------------------------------

Some aspects of USP1 regulation are different from the USP12 and USP46, as USP1 is a much larger enzyme, and it cannot be hyper-activated by WDR20. We therefore wondered whether the 1:2 stoichiometry is also conserved in this important DNA repair enzyme. We carried out SEC-MALLS of the purified USP1/UAF1 complex and the molecular weight obtained was approximately 220 KDa which closely corresponds to the 1:2 complex (235 KDa) rather than a 1:1 complex (160 KDa). Similar to the USP12/UAF1 MALLS data ([Fig. 2](#f0010){ref-type="fig"}a), the molecular weight was not constant within the peak suggesting a dynamic equilibrium between the two states of the complex ([Fig. 5](#f0025){ref-type="fig"}a). We then performed the UAF1 binding assay with His-USP1 on the SPR chip ([Fig. 5](#f0025){ref-type="fig"}b, c). Again, we observed a two-step binding, and although the high RU values for the second step suggests an additional unexplained background process, the fitting identified similar affinities for USP1 to those observed for USP12. Thus from our SPR result in addition to the MALLS data, we could confirm the presence of this unusual two-step binding in USP1.

4. Discussion and conclusions {#s0080}
=============================

Here we present a series of structures that contribute to the understanding of regulation of DUBs by non-substrate partners. In our analysis we identified two possible binding sites for UAF1 on USP12-Ub ([Fig. 5](#f0025){ref-type="fig"}d), that are conserved from USP46. The two UAF1 binding sites are distant from the catalytic centre and binding of UAF1 did not induce significant rearrangements in the USP structure. Thus it is very hard to envision from these structures how USP12 is activated by UAF1, especially when the activation is due to an increase in k~cat~ and not K~M~. It is possible that UAF1 binding stabilizes the flexible USP12 "fingers", transforming it into a catalytically proficient state and this may not be visible since we compare it to a ubiquitin-bound USP structure. Therefore an apo-structure of USP12 could shed more light on this issue.

The binding analysis shows that Interface 1 provides the high affinity interaction that is responsible for the activation of the USP. We measure a binding affinity in the order of 4 nM with extremely slow dissociation. The affinity is less tight than the 0.1 nM observed for USP46 by [@b0230], most likely due to differences in the experimental setup. Their lowest concentration of UAF1 used was far above the reported K~D~ (sevenfold), and the K~D~ was estimated based on very slow dissociation constant derived from the global kinetic fit. Overall, the structure of USP12-Ub/UAF1~580~ and the UAF1 mediated activation through Interface 1 bears close resemblance to the published data on USP46 ([@b0230]), again highlighting the high degree of conservation between these USPs. The Interface 1 has a relatively small surface area, with a predominance of charged interactions. For such a small interface, even the observed affinity of 4 nM is rather surprising since such strong binding between two proteins is rarely mediated by interfaces having less than 1000 Å^2^ buried surface area ([@b0015]). However, previous reports have suggested the importance of the fingers domain for UAF1 binding and activation ([@b0175]). It is still unclear how S313 phosphorylation which is present in the long insert of USP1 could play a role in UAF1 binding ([@b0215]), as the (shorter) corresponding region on USP12 is not involved in UAF1 binding for either of the interfaces.

In the USP12/UAF1~580~ complex we observe a conserved second interface (Interface 2) at the backside of the ubiquitin binding cleft. The buried surface area of this interface is larger than for Interface 1, and the contact is more hydrophobic, indicating that its properties are very different. Our binding data confirm the presence of a secondary interaction, with an affinity of ∼300 nM and fast kinetics. Unfortunately we were unable to validate this interface by mutational analysis. It is possible that this is due to the large surface area involved in this binding. Additionally the surface shape complementarity between the extended loop in USP12 and the relatively concave architecture of ancillary domain and β-propeller in the UAF1 molecule could contribute to the interaction primarily by backbone interactions.

The two binding interfaces on UAF1 seem independent of each other as they reside in distant parts of the protein. Thus mutating residues on Interface 1 is unlikely to affect binding to Interface 2 or *vice versa*. Our binding studies with the UAF1~3X~ mutant showed binding to the high affinity site at very high concentrations and no binding to the low affinity site. This could mean that UAF1 can only bind the low affinity site once the high affinity site has been fully occupied. It is possible that high overall flexibility in USP12 in the unbound state prevents binding to the low affinity site, thereby making the high affinity binding mandatory for binding the second UAF1.

During revision of this manuscript, a structure for the USP12/UAF1/WDR20 complex was published ([@b0140]). In this structure WDR20 binds to a number of structural elements at the palm domain of USP12 with an affinity of 7 nM. Interestingly, the binding interface for WDR20 partially overlaps with the second binding site of UAF1 on USP12 ([Supp. Fig. 1d](#s0100){ref-type="sec"}), but the contacts are very different, explaining how a F287A/V279D mutation can disrupt WDR20 binding whereas F287A does not affect the UAF1 interface, which is dominated by backbone interactions in this area. The partial overlap of the binding interfaces and the high affinity of WDR20 suggests that WDR20 binding to USP12/UAF1 can either prevent binding of the second UAF1 molecule or it can actively compete out UAF1 if it is bound to the USP12/UAF1 complex. The partial overlap of this interface could hint towards a possible regulatory role for the second UAF1 binding.

The second binding of UAF1 to USP12 does not seem to play a role in the activation of USP12 on a minimal substrate. Meanwhile the effect of the second UAF1 binding on the catalytic activity of USP12 against one of its natural substrates remains to be tested and this could yield more insight on the possible function of this regulatory event. In any case, the conservation of the 1:2 stoichiometry and the two step binding of UAF1 in this small family of USPs highlights the importance of the second binding and implies that the binding could be important for functions which are independent of activation on a minimal substrate.

All available data ([@b0030], [@b0195]) and the high affinity with slow off-rates indicate that USP12/UAF1 form a constitutive complex in cells. In contrast, the fast kinetics of the second binding site indicates that it could play a role in regulation. This is in line with the recent quantitative analysis of protein abundance in HeLa cells that place the concentration of USP12 and UAF1 at 2 and 77 nM, respectively ([@b0070]). At that concentration the first interface would be fully saturated, and a significant fraction of the USPs would start to bind a second molecule. This means that the second binding could potentially play an important regulatory role.
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![Crystal structure analysis shows two possible binding options for USP12. A) Constructs used for the present study. B) Crystal structure of USP46-Ub-VME in cartoon representation. C) Crystal structure of UAF1~580~ coloured in a rainbow representation. D) Crystal structure of USP12~FL~-Ub/UAF1~580~ showing UAF1~580~ bound to Interface 1. E) Zoomed Interface 1 between UAF1~580~ and USP12~FL~-Ub showing the interface residues. F) Crystal structure of USP12~FL~-Ub/ UAF1~580~ showing UAF1~580~ bound to Interface 2. G) Zoomed Interface 2 between UAF1~580~ and USP12~FL~-Ub showing the interface residues. (Colours in panel B, D--G: Ub in yellow, other proteins as in A).](gr1){#f0005}

![USP12/UAF1 has 1:2 stoichiometry. A) SEC-MALLS analysis of USP12~FL~-Ub/UAF1~580~ (8 μM) shows a molecular weight corresponding to a 1:2 complex. B) SEC-MALLS analysis of USP12~FL~-Ub/UAF1~FL~ at high concentration (42 μM) shows a dynamic equilibrium between high molecular weight species and the 1:2 complex in agreement with the SAXS data. C--E) Experimental SEC-SAXS curve of USP12~FL~-Ub/UAF1~FL~ fits better with the scattering curve based on the structure of the 1:2 complex as compared to the 1:1 complex at either of the two interfaces. F) OLIGOMER fit of the Experimental SEC-SAXS curve of USP12~FL~-Ub/UAF1~FL~.](gr2){#f0010}

![UAF1 binds USP12 in two steps with different affinities. A) Qualitative SPR analysis of five successive injections of UAF1~FL~ on immobilized USP12~WT~, raw data show how initial injections show slow kinetics, and binding at higher concentrations displays fast off-rates. B) Fitting quantitative SPR analysis of UAF1~FL~ to USP12~WT~, obtained from 15 successive injections of UAF1~FL~. Curve is fit to a two-step binding model with K~D~ as indicated. C) Cleavage of Ub-Rhodamine by USP12~WT~ at different concentrations of UAF1~FL~(10 nM--1250 nM). D) Initial rates of USP12~WT~ plotted as a function of UAF1~FL~ concentration shows the importance of high affinity site for activation. E) Michaelis Menten analysis of USP12~WT~ (100 nM) alone and in two different concentrations of UAF1~FL~ (100 nM, 1250 nM) shows that the second binding of UAF1 leads to no further activation.](gr3){#f0015}

![Interface 1 is the high affinity site and is responsible for activation by UAF1. A) Comparing Qualitative SPR analysis of five successive injections of UAF1~FL~ and UAF1~3X~ on immobilized USP12~WT~ and USP12~E190K~ shows differences in binding characteristics. B) Semi-quantitative SPR analysis of UAF1~FL~ to USP12~WT~ and USP12~E190K~ mutant highlights weaker binding of the mutant to the high affinity interface. C) Semi-quantitative SPR analysis of UAF1~3X~ to USP12~WT~ and USP12~E190K~, curves show disruption of binding in USP12~WT~ which is rescued by the USP12~E190K~ mutant. D) Cleavage of Ub-Rhodamine by USP12~E190K~ at different concentrations of UAF1~FL~ shows loss in activation by UAF1~FL~. E) Comparison of initial rates of USP12~WT~ and USP12~E190K~ at different UAF1~FL~ concentrations shows that when high affinity interaction is lost the activity is impaired. F) Comparison of initial rates of USP12~WT~ and USP12~E190K~ at different concentrations of UAF1~3X~ shows the rescue of activation by the USP12~E190K~ mutant. G) Comparing Qualitative SPR analysis of five successive injections of UAF1~FL~ on immobilized USP12~WT~ and USP12 interface 2 mutants shows no significant change in binding characteristics. H) Semi-quantitative SPR analysis of UAF1~FL~ to Interface 2 mutant USP12~RRFR~ and USP12~WT~ shows identical binding.](gr4){#f0020}

![The two step UAF1 binding is conserved in USP1. A) SEC-MALLS analysis of USP1/UAF1~FL~ (6 μM) shows a molecular weight corresponding to the 1:2 complex. B) Qualitative SPR analysis shows that USP1 has conserved the two-step binding to UAF1~FL~, with similar kinetics. C) Fitting of quantitative SPR analysis of UAF1~FL~ to USP1 obtained from 15 successive injections of UAF1~FL~ to quantify the K~D~ values. Curve is fit to a two-step binding model with affinities as indicated. D) UAF1 binds USP12 at the fingers sub-domain which activates USP12 and then UAF1 also binds on the backside of the ubiquitin binding cleft.](gr5){#f0025}

###### 

Crystallography details.

  Data collection                                                                             
  ------------------------------------- -------------------------- -------------------------- --------------------------
  Wavelength (Å)                        0.93                       0.92                       1.00
  Resolution (Å)                        28.41--1.85 (1.90--1.85)   48.97--2.30 (2.35--2.30)   47.41--2.79 (2.92--2.79)
  Space Group                           C 2 2 21                   P 2 21 21                  I 2 2 2
  Unit Cell a, b, c (Å)                 91.95 104.66 135.31        73.30 131.60 148.67        103.68 152.82 182.93
  CC~1/2~                               0.999 (0.720)∗             0.999 (0.585)              0.995 (0.638)
  R~merge~                              0.12 (0.84)                0.05 (1.0)                 0.08 (0.72)
  R~pim~                                                           0.04 (0.84)                0.06 (0.57)
  I/σI                                  17.68 (2.0)                16.1 (1.4)                 10.4 (1.6)
  Completeness (%)                      98.8 (99.7)                99.6 (95.9)                99.3 (94.8)
  Redundancy                            3.56 (3.3)                 4.5 (4.1)                  4.5 (4.3)
                                                                                              
  *Refinement*                                                                                
  Unique Reflections (nr)               55,291                     64,580                     36,148
  Atoms total (nr)                      3442                       8586                       7290
  Protein atoms (nr)                    3192                       8195                       7266
  Solvent atoms (nr)                    250                        391                        24
  B-factors                             31.9                       58.3                       72.4
  TLS groups                            4                          4                          4
  R~work~/R~free~ (%)                   16.6/19.4                  18.5/22.4                  20.8/25.9
  Rmsd bond lengths (Å)                 0.017                      0.007                      0.014
  Rmsd bond angles (°)                  1.758                      1.235                      1.642
  Ramachandran (%) Preferred/outliers   97.89/0                    97.27/0.30                 95.5/0.34
  Molprobity score                      1.01                       0.82                       1.77
  PDB code                              5L8H                       5L8E                       5L8W

High resolution shell in parentheses; (∗ -- Reprocessed with aimless).

###### 

Michaelis Menten analysis of USP12~WT~ with UAF1.

  Protein                      K~cat~ (×10^−2^s^−1^)   K~M~ (μM)   K~cat~/K~M~ (M^−1^ s^−1^)
  ---------------------------- ----------------------- ----------- ---------------------------
  USP12~WT~ (100 nM)           0.076                   50          0.15 × 10^2^
  USP12~WT~ + UAF1 (100 nM)    2.6                     50          5.20 × 10^2^
  USP12~WT~ + UAF1 (1250 nM)   3.3                     64          5.15 × 10^2^
